RxDoctor Payments Data

John Larrimer, MD

Endocrinology, Diabetes & Metabolism · Reynoldsburg, OHNPI 1073565354

Payments from drug & device makers

$5,518in general payments, 2019–2025

Across 296 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$784
  • Lilly USA, LLC$637
  • AbbVie$475
  • IBSA Pharma Inc.$326
  • Sanofi-aventis U.S. LLC$324
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,510100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,518 in reported general payments places this provider in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$78,921
Medicare patients
391
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$151,321
TrulicityDulaglutide74$96,724
MounjaroTirzepatide37$66,845
FarxigaDapagliflozin Propanediol52$61,811
JardianceEmpagliflozin37$46,286
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$36,092
Tresiba Flextouch U-200Insulin Degludec34$35,110
SynthroidLevothyroxine Sodium418$29,723
Novolog FlexpenInsulin Aspart81$27,896
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$26,896
Fiasp FlextouchInsulin Aspart (Niacinamide)13$22,763
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$19,823
Xigduo XrDapaglifloz Propaned/Metformin13$19,132
Humalog Kwikpen U-100Insulin Lispro39$11,406
Tresiba Flextouch U-100Insulin Degludec12$7,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$637$169,160123 claims
Novo NordiskOzempic$1,327$151,32181 claims
AstraZenecaFarxiga$784$61,81152 claims
Boehringer IngelheimJardiance, Jentadueto Xr$194$50,79748 claims
AbbVieSynthroid, Armour Thyroid$475$34,748457 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$94$7,635773 claims
Sanofi-aventis U.S. LLCLantus$324$3,96626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Reynoldsburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →